Postinfectious bronchiolitis obliterans in children: lessons from bronchiolitis obliterans after lung transplantation and hematopoietic stem cell transplantation.
10.3345/kjp.2015.58.12.459
- Author:
Jinho YU
1
Author Information
1. Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jyu3922@gmail.com
- Publication Type:Review
- Keywords:
Bronchiolitis obliterans;
Post-infectious;
Child;
Inflammation;
Fibrosis
- MeSH:
Adrenal Cortex Hormones;
Airway Obstruction;
Bronchiectasis;
Bronchioles;
Bronchiolitis Obliterans*;
Bronchiolitis*;
Child*;
Diagnosis;
Fibrosis;
Forced Expiratory Volume;
Hematopoietic Stem Cell Transplantation*;
Hematopoietic Stem Cells*;
Humans;
Infant;
Inflammation;
Lung Diseases;
Lung Diseases, Obstructive;
Lung Transplantation*;
Lung*;
Perfusion;
Respiratory Function Tests;
Respiratory Tract Infections;
Spirometry
- From:Korean Journal of Pediatrics
2015;58(12):459-465
- CountryRepublic of Korea
- Language:English
-
Abstract:
Postinfectious bronchiolitis obliterans (PIBO) is an irreversible obstructive lung disease characterized by subepithelial inflammation and fibrotic narrowing of the bronchioles after lower respiratory tract infection during childhood, especially early childhood. Although diagnosis of PIBO should be confirmed by histopathology, it is generally based on history and clinical findings. Irreversible airway obstruction is demonstrated by decreased forced expiratory volume in 1 second with an absent bronchodilator response, and by mosaic perfusion, air trapping, and/or bronchiectasis on computed tomography images. However, lung function tests using spirometry are not feasible in young children, and most cases of PIBO develop during early childhood. Further studies focused on obtaining serial measurements of lung function in infants and toddlers with a risk of bronchiolitis obliterans (BO) after lower respiratory tract infection are therefore needed. Although an optimal treatment for PIBO has not been established, corticosteroids have been used to target the inflammatory component. Other treatment modalities for BO after lung transplantation or hematopoietic stem cell transplantation have been studied in clinical trials, and the results can be extrapolated for the treatment of PIBO. Lung transplantation remains the final option for children with PIBO who have progressed to end-stage lung disease.
